Dr. Warren is a Senior Investigator and Head of the Brain Tumor Section of the Pediatric Oncology Branch of the National Cancer Institute, where she has worked for over 25 years. She attended medical school at Tufts University (Boston), followed by a Pediatric Residency at Children’s National Medical Center (Washington, DC) and a Pediatric Oncology Fellowship at the National Cancer Institute. She serves on a number of advisory committees including the NCI/CTEP Brain Malignancies Steering Committee, the NCI Clinical Trials and Translational Research Advisory Committee Ad hoc Working Group on Glioblastoma, the US Pediatric Brain Tumor Working Group, and is the current chair of the Response Assessment in Pediatric Neuro-Oncology (RAPNO) committee. Her ongoing research at NCI combines her training, experience and expertise in pharmacology and neuro-oncology in a research program that focuses on developing strategies to optimize clinical trial design and improve efficiency using a rational therapeutic paradigm based on preclinical pharmacokinetic and biologic information. This includes selecting and delivering agents specific for each patient’s tumor, and achieving effective drug exposures at the tumor site, thereby reducing the number of patients receiving ineffective therapies or inadequate dosing while preventing excessive dosing and accompanying toxicities. Her working hypothesis is that concentrating efforts to obtain specific preclinical information will lead to rational trial design and ultimately improved efficacy and quality of life for children with CNS tumors.